183 related articles for article (PubMed ID: 24595498)
21. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
22. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
23. Atazanavir: A novel once-daily protease inhibitor.
Piliero PJ
Drugs Today (Barc); 2004 Nov; 40(11):901-12. PubMed ID: 15645003
[TBL] [Abstract][Full Text] [Related]
24. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.
Barrail-Tran A; Mentré F; Cosson C; Piketty C; Chazallon C; Gérard L; Girard PM; Taburet AM
Antimicrob Agents Chemother; 2010 Feb; 54(2):614-9. PubMed ID: 19995932
[TBL] [Abstract][Full Text] [Related]
25. pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions.
Kis O; Zastre JA; Ramaswamy M; Bendayan R
J Pharmacol Exp Ther; 2010 Sep; 334(3):1009-22. PubMed ID: 20507927
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacology, pharmacokinetic features and interactions of atazanavir].
López-Cortés LF
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():2-8. PubMed ID: 20116610
[TBL] [Abstract][Full Text] [Related]
27. MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting.
Dahan A; Amidon GL
Int J Pharm; 2010 Feb; 386(1-2):216-20. PubMed ID: 19944137
[TBL] [Abstract][Full Text] [Related]
28. Intestinal permeability study of minoxidil: assessment of minoxidil as a high permeability reference drug for biopharmaceutics classification.
Ozawa M; Tsume Y; Zur M; Dahan A; Amidon GL
Mol Pharm; 2015 Jan; 12(1):204-11. PubMed ID: 25423288
[TBL] [Abstract][Full Text] [Related]
29. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.
DiCenzo R; Peterson DR; Cruttenden K; Mariuz P; Rezk NL; Hochreiter J; Gelbard H; Schifitto G
Antimicrob Agents Chemother; 2008 Sep; 52(9):3035-9. PubMed ID: 18573930
[TBL] [Abstract][Full Text] [Related]
30. Change in tolbutamide permeability in rat jejunum and Caco-2 cells by Sho-saiko-to (Xiao Chai Hu Tang), a Chinese traditional medicine.
Nishimura N; Uemura T; Iwamoto K; Naora K
J Pharm Pharmacol; 2010 May; 62(5):651-7. PubMed ID: 20609069
[TBL] [Abstract][Full Text] [Related]
31. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
[TBL] [Abstract][Full Text] [Related]
32. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.
Dahan A; Sabit H; Amidon GL
Drug Metab Dispos; 2009 Oct; 37(10):2028-36. PubMed ID: 19589874
[TBL] [Abstract][Full Text] [Related]
33. P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats.
Zhang Y; Wang C; Liu Z; Meng Q; Huo X; Liu Q; Sun P; Yang X; Sun H; Ma X; Liu K
Pharmacol Rep; 2018 Apr; 70(2):243-250. PubMed ID: 29475007
[TBL] [Abstract][Full Text] [Related]
34. Effect of prolonged omeprazole administration on segmental intestinal Mg
Suksridechacin N; Kulwong P; Chamniansawat S; Thongon N
World J Gastroenterol; 2020 Mar; 26(11):1142-1155. PubMed ID: 32231419
[TBL] [Abstract][Full Text] [Related]
35. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
36. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Alsenz J; Steffen H; Alex R
Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
[TBL] [Abstract][Full Text] [Related]
38. Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein.
Chinn LW; Gow JM; Tse MM; Becker SL; Kroetz DL
J Antimicrob Chemother; 2007 Jul; 60(1):61-7. PubMed ID: 17510066
[TBL] [Abstract][Full Text] [Related]
39. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines.
Lo YL
J Control Release; 2003 Jun; 90(1):37-48. PubMed ID: 12767705
[TBL] [Abstract][Full Text] [Related]
40. Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.
Guiard-Schmid JB; Poirier JM; Bonnard P; Meynard JL
J Acquir Immune Defic Syndr; 2006 Mar; 41(3):393-4; author reply 394. PubMed ID: 16540944
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
